NBY Novabay Pharmaceuticals Inc.
- 0 P/E
- 7.47 P/S
- 4.78 P/B
- -0.271 EPS
- -2,638.06% Cash ROIC
- 4.98 Cash Ratio
- 0.00 / N/A % Dividend
- 212,843.00 Avg. Vol.
- 25.77M Shares
- 49.6M Market Cap.
NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
GlobeNewswire (press release) - May 2, 2013
NIS - Apr 29, 2013
Globe and Mail - May 2, 2013
Reuters Key Development - Dec 6, 2012
Reuters Key Development - Dec 5, 2012
Reuters Key Development - Aug 27, 2012
Reuters Key Development - May 2, 2012
Reuters Key Development - Apr 19, 2012
Reuters Key Development - Mar 20, 2012
Reuters Key Development - Jan 9, 2012